DOCUMENT
Supplementary_Table_S1_-_Revision.docx (22.2 kB)
DOCUMENT
Supplementary_Table_S2_-_Revision.docx (20.09 kB)
DOCUMENT
Supplementary_Table_S3.docx (16.47 kB)
DOCUMENT
Supplementary_Table_S4.docx (16.33 kB)
DOCUMENT
Supplementary_Table_S5.docx (17.93 kB)
1/0
Cost-effectiveness of pembrolizumab plus chemotherapy as first line treatment in PD-L1-positive metastatic TNBC. Supplementary Tables.
dataset
posted on 2022-07-07, 07:52 authored by Joyce O'Shaughnessy, Nicolas Cappoen, Celine Le Bailly De Tilleghem, Zheng-Yi Zhou, Emma Gray, Wilbur James. Pan, Amin Haiderali, Peter Fasching, Min Huang, Mitashri Chaudhuri
Supplementary Table S1. AIC/BIC of parametric function fitting for OS, PFS and ToT
Supplementary Table S2. AE related hospitalization costs (2021 USD)
Supplementary Table S3. Summary of scenario analyses results
Supplementary Table S4. Summary of subgroup analysis results
Supplementary Table S5. Cost-effectiveness results for pembrolizumab plus chemotherapy (weighted average) vs. chemotherapy (weighted average)
